The minimum clinically important difference: which direction to take

T. H. P. Draak*, B. T. A. de Greef, C. G. Faber, I. S. J. Merkies, PeriNomS Study Grp

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

27 Citations (Web of Science)

Abstract

Over the past decades in modern medicine, there has been a shift from statistical significance to clinical relevance when it comes to interpreting results from clinical trials. A concept that is increasingly being used as a surrogate for clinical relevance and effect size calculation is the minimum clinically important difference (MCID). In this paper, an overview is presented of the most important aspects of the MCID concept used in research trials and a discussion of what this means for the neurological patient in clinical trials and daily practice is given. Is the MCID the best outcome measure cut-off to be implemented?

Original languageEnglish
Pages (from-to)850-855
Number of pages6
JournalEuropean Journal of Neurology
Volume26
Issue number6
DOIs
Publication statusPublished - Jun 2019

Keywords

  • minimum clinically important difference (MCID)
  • QUALITY-OF-LIFE
  • STATISTICAL SIGNIFICANCE
  • INTRAVENOUS IMMUNOGLOBULIN
  • INTRAINDIVIDUAL CHANGES
  • PATIENT
  • RELEVANCE
  • TRIAL

Cite this